【摘要】 目的评价咪达唑仑复合瑞芬太尼靶控输注麻醉技术在内镜粘膜下剥离术(ESD)中的应用疗效及安全性。方法回顾分析我院2011年1~7月间85例应用咪达唑仑复合瑞芬太尼靶控输注麻醉技术行ESD术的患者,持续监测并定时记录患者在ESD术中的心率、呼吸、血压、血氧饱和度的变化,术后随访患者对术中的记忆和疼痛的感觉及术后恶心、呕吐等不良反应。结果 85例患者在咪达唑仑复合瑞芬太尼靶控输注麻醉下行ESD全部成功,82例(96.47%)麻醉效果满意,3例患者术后主诉术中有轻度痛感,能忍受。5例术中出现循环及呼吸等不良反应经对症治疗后好转。结论咪达唑仑复合瑞芬太尼靶控输注清醒镇痛的麻醉技术用于ESD术患者的镇静、镇痛效果满意,不良反应少,能为患者提供安全、满意的ESD手术条件,值得临床推广应用。更多还原

【Abstract】 Objective To validate the safety and effectiveness of target-controlled infusion(TCI) with Midazolam plus Remifentanil during endoscopic submucosal dissection(ESD). Methods 85 patients undergoing ESD were anaesthetized by target-controlled infusion with Midazolam plus Remifentanil. Blood drug level, arterial blood pressure(BP), heart rate (HR) and oxygen saturation(SpO2) were monitored during the peri-procedure stage. Results All patients performed the ESD operation successfully. 3 patients complained the abdominal pain which were endurable.5 patients appeared the cardiorespiratory side effect and were improved after symptomatic treatment.No sedation-related complications were encountered in all patients.As for the questionnaire survey, most respondents, in particular the operation doctors, supported the use of TCI with Midazolam plus Remifentanil during ESD. Conclusion Target-controlled infusion with Midazolam plus Remifentanil is safe and effective during ESD,which can make the patients feel safe and satisfied.更多还原